and cell cycle regulation 7) . Qualitative changes in transcripts modified hepatortoxicity significantly in Pparα-null mice, leading a conclusion that PPARα is required for PFOA-induced cellular alterations in mouse hepatocytes.
Recently, Hays et al. demonstrated that a weak PPARα ligand, bezafibrate, induces cholestasis without neoplastic changes in Pparα-null mice, and have concluded that PPARα protects against potential cholestasis, while it facilitates tumor promotion 9) . They have also demonstrated that a very specific PPARα ligends, Wy-14,643, does not induce cholestastis 9) . Thus, the toxicity profile of a chemical that up-or down-regulates via PPARα-dependent and independent pathways may be modified depending on its affinity to PPARα and its dose.
A reasonable conjecture would be that PFOA, which is known as a PPARα weak ligand, might also induce cholestatic disease in Pparα-null mice. No study on PFOA has ever investigated so far biliary duct toxicity. This study examined whether PFOA has the potential for inducing cholestatic disease and PPARα has a role in protecting against chemical induced choestasis. We investigated whether PFOA induces cholestasis in Pparα-null mice and the dose-response relationship between PFOA and toxicological responses in Pparα wild and null mice. It is well known that cholestasis is not a common response in mice, although it is a very common response to xenobiotics including therapeutic drugs in human 10) . Thus, the null genotype of PPARα might reveal bile duct toxicity of many PPARα inducers otherwise overlooked, although they may be recognized only at very high doses 11) .
Subjects and Methods

Animals and treatment
Wild-type mice (129S4/SvlmJ) and Pparα-null mice (129S4/SvJae-Pparα tm1Gonz /J) were originally provided from Dr. Frank J. Gonzalez (National Cancer Institute, Bethesda, MD) and housed in Kyoto University Institute of Laboratory Animals. All experiments were performed with male mice aged 8-10 wk (22-25 g ). 39 wild-type mice and 40 Pparα-null mice were randomly assigned to four groups in accordance with the administered doses of PFOA (0, 12.5, 25, 50 µmol/kg/d). PFOA ammonium salt (>98% purity) was purchased from Fluka Chemical (Steinheim, Switzerland) and dissolved in deionized water. Mice were treated by oral gavage (8 ml/kg) daily for 4 wk and killed by euthanasia at the end of 4 wk, at which time, blood, liver and bile were collected.
Livers were weighed, and the tissue was fixed in 10% neutral-buffered formalin for light microscopic examination or 1% glutaraldehyde/1.44% paraformaldehyde solution for transmission electron microscopy for ultrastructural examination. The remaining portion was flashfrozen in liquid nitrogen and stored at -80˚C.
Biochemical measurements
Biochemical analyses were performed on plasma samples. These analyses were examined by Nagahama Life Science Laboratory, Oriental Yeast Co. Ltd. (Shiga, Japan), and included aspartate aminotransferase (AST) and alanine aminotransferase (ALT) as hepatocellular damage markers, total bilirubin (T-Bil) and total bile acid (TBA) as cholestatic markers, and total cholesterol (TCho) and triglyceride (TG) as fat metabolism markers.
Histology
For light microscopy, livers were processed by routine paraffin sectioning and staining with hematoxylin and eosin (HE). For the determination of apoptosis, a terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling, TUNEL, test was performed. An Apop Tag kit (Oncor, Gaithersburg, MD) was used according to the manufacturer's recommendations.
For ultrastructural studies, livers were post-fixed in 1% osmium tetroxide in 0.2 M phosphate buffer, routinely dehydrated through a graded ethanol series, and embedded in Epon using the Luft method 12) . Sections were cut in 80 µm on a Leica EM UC6 ultramicritome (Hitachi, Tokyo, Japan) with a diamond knife, and stained by the Reynolds method 13) . The grids were examined under a Hitachi 7650 transmission electron microscope (Hitachi).
Analysis of PFOA
Determination of PFOA in whole blood, bile and liver was performed using a modification of a method originally developed by Yline et al 14) . Diluted blood, bile or homogenized liver was combined with 10 µl of a 1 µg/ml solution of 13 C 2 -PFOA as an internal standard. One milliliter of tetrabutylammonium hydrogen sulfate and 2 ml 0.5 M sodium carbonate buffer solution (pH adjusted to 10) were combined and vortexed, then 2 ml methyl tertbutyl ether (MTBE) was added and vortexed. The tube was centrifuged to separate the aqueous and organic phases, and 1 ml of the MTBE layer was extracted, transferred to a glass tube, and evaporated to dryness at 38˚C under a gentle stream of dry nitrogen. The residue was then redissolved in 100 µl of 100 mM benzyl bromide acetone for 1 h at 80˚C and transferred to an autosampler vial. Extracts were analyzed using gas chromatography-mass spectrometry (Agilent 6890GC/5973MSD, Agilent Technologies Japan, Ltd., Tokyo, Japan) in electron impact ionization mode. PFOA was separated on an HP-5MS column (30 m length, 0.25 mm i.d., 0.25 µm film thickness) with a helium carrier gas. Splitless injections (2 µl) were performed with the injector set at 220˚C, and the split was opened after 1.5 min. The initial oven temperature was 60˚C for 1.5 min, ramped at 15˚C min -1 to 100˚C, and then at 40˚C min -1 to 240˚C. Recoveries of 13 C 2 PFOA from biological samples (n=3) were 94 ± 2.6% for blood, 97 ± 4.4% for bile and 94.7 ± 4.9% for liver, respectively. in the liver 8-OHdG/dG levels were measured as an indicator of oxidative DNA damage. The frozen livers were minced and gently homogenized in a homogenizer by 5 strokes in lysis solution (Qiagen, Tokyo, Japan), DNA was extracted from mice frozen liver using a DNA Extractor WB kit (Wako Pure Chemical Industries, Ltd., Osaka, Japan) 15) . DNA was digested completely to nucleotides by combined treatment with Nuclease P1 (Wako Pure Chemical Industries, Ltd.) and alkaline phosphatase (Sigma Chemical Co., St. Louis, MO). Then the resulting deoxynucleoside mixture was injected into a high performance liquid chromatography apparatus (LC-10ADvp, Shimadzu, Kyoto, Japan) equipped with both a UV detector (SPD-10AVvp, Shimadzu) and an electrochemical detector (Coulochem model-5200-2, ESA, MA) 16) . Each liver was examined in duplicate and the means were reported.
Measurement of 8-hydroxydeoxyguanosine
Quantitative RT-PCR analysis for multidrug resistance protein 2 (Mdr2) and tumor necrosis factorα (TNF-α)
Quantitative real-time (RT)-PCR was used to study Mdr2 and Tnf mRNA expression in the liver. Total RNA was extracted from the liver using RNeasy Lipid Tissue Mini Kit (Qiagen). Aliquots (10 ng) were amplified using QuantiTect ® SYBR ® Green RT-PCR (Qiagen). Quantification of the amplified products was performed on an ABI PRISM 7700 Sequence Detection System (Applied Biosystems Japan, Tokyo, Japan). All expression data were normalized to glyceraldehyde 3-phophate dehydrogenase (GAPDH) mRNA from the same individual sample, to correct for differences in efficiency of RNA extraction and quality.
The following primers were used for RT-PCR: GAPDH: forward, 5'-ATGGTGAAGGTCGGTGTGAA-3'; reverse, 5'-GAGTGGAGTCATACTGGAAC-3' 17) , corresponding to GenBank accession number M32599; Mdr2: forward, 5'-ATCCTATGCACTGGCCTTCTGGT-3'; reverse, 5'-GAAAGCATCAATACAGGGGGCAG-3' 18) , corresponding to GenBank accession number NM_008830; Tnf forward, 5'-TCTTCTCAAAATTCGAGTGACAAG-3'; reverse, 5'-GAGAACCTGGGAGTAGACAAGGTA-3', (note: designed in our lab) corresponding to GenBank accession number NM_013693.
Determination of bile acid/phospholipid ratio (BA/PL) in bile
Commercially available kit was used for determination of bile acid and phospholipid contents in bile (Wako Pure Chemical Industries). For bile acid determination, 0.1 µl bile was diluted in 200 µl double distilled H 2 O, that was added to 500 µl 3-α-hydroxysteroid dehydrogenase, incubated at 37˚C for 10 min, added to 500 µl response fixing solution, and absorbance was read at 560 nm using a Hitachi U-2000A spectrophotometer (Hitachi). For phospholipid determination, 0.4 µl bile was diluted in 20 µl double distilled H 2 O, that was added to 3.0 ml color reagent (Phospholipid-C Test Wako, Wako Pure Chemical Industries), incubated at 37˚C for 5 min, and absorbance was read at 600 nm against a color reagent blank.
Western blot analysis of BSEP and MRP2
Western blot analysis was carried out for quantification of the protein levels of the canalicular bile salt export pump (BSEP) and the canalicular multidrug resistanceassociated protein 2 (MRP2). Membrane protein samples mixed with sample loading buffer (15 µg protein/lane) were loaded after heating for 10 min at 70˚C onto a 3-8% Tris-acetate gel. Following electrophoresis, proteins in the gel were electrotransferred to PVDF-plus membranes (Immobilon-P Transfer Membrane; Millipore) for 1 h at 30 V at 4˚C. Membranes were blocked for 1 h at room temperature with 5% non-fat dry milk in Tris-buffered saline that contained 0.05% Tween-20 (TBS-T). Blots were then incubated for 1 h at room temperature with the primary polyclonal antibody of rabbit BSEP, which was kindly provided by Rexue Wang, (British Columbia Cancer Research Center, Vancouver, BC, Canada) and rat MRP2, which was kindly provided by Bruno Stieger (University Hospital, Zurich, Switzerland). GAPDH antibody was used as a loading control. Each primary antibody was diluted in blocking buffer (1:5,000 for BSEP, 1:4,000 for MRP2, 1:1,000 for GAPDH). After thorough washing, blots were incubated with donkey anti-rabbit IgG horseradish peroxidase-linked secondary antibody (1:4,000 dilution with 5% non-fat milk in TBS-T) for 1 h. Immunoreactive bands were detected with an enhanced chemical luminescence (ECL) kit (Immobilon Western; Millipore). BSEP and MRP2 proteins were visualized by exposure to Fuji Medical X-Ray film (FUJIFILM Medical Co., Ltd, Tokyo, Japan).
Statistical analysis
Nine or 10 animals were studied in each group. All results were expressed as mean ± SD. Comparisons between two groups were performed using an unpaired Student's t test, and Dunnett's test for dose-response experiments. Levene's test was used to assess the equal-ity of variance. Trend test was performed using Jonckheere's test. p<0.05 was considered to be statistically significant. Statistical analyses were done on SAS software (ver.8.2).
Results and Discussion
Body and liver weights (Table 1) Body and liver weight changes after exposure to PFOA in both groups of mice are shown in Table 1 . Absolute and relative liver weights (% body weight) were increased approximately three fold in wild-type or Pparα-null mice, and induction of hepatomegaly reached plateau levels in both genetic backgrounds at doses higher or equal to 12.5 µmol/kg. These results demonstrated that PFOA induced hepatomegaly through non-PPARα-mediated pathways as previously reported 19) .
Biochemical analysis (Table 2)
In wild-type mice, judging from the plasma AST and plasma ALT values, 12.5 or 25 µmol/kg PFOA caused hepatocellular damages with slight changes in T-Bil and TBA. The hepatocellular damages seemed to increase with increase in dose. Mild cholestasis was apparent at 50 µmol/kg, at which dose mild increases in T-Bil and TBA were observed. T-Cho was decreased after treatment with PFOA at 25 and 50 µmol/kg. TG was increased after treatment with PFOA at 12.5 and 25 µmol/kg, but was the same level at 50 µmol/kg.
In Pparα-null mice, 12.5 or 25 µmol/kg PFOA treatment induced mild hepatocellular damages indicated by ALT but those changes were not accompanied by elevation of T-Bil or TBA. At 50 µmol/kg, PFOA, however, induced extensive hepatocellular damages and cholestasis simultaneously with a sharp contrast with wild cholestasis in wild mice. TG metabolism was significantly disturbed, even at 12.5 µmol/kg, while cholesterol metabolism was disturbed only at the highest dose of 50 µmol/kg.
Biochemical analysis suggested a significant modification of liver toxicity of PFOA by PPARα. Hepatocytes were more vulnerable than bile duct cells to PFOA in wild-type mice. In contrast, ablation of PPARα rendered the hepatocytes tolerable to PFOA-induced damage, at doses lower than 50 µmol/kg, while extensive hepatic and bile duct injuries occurred at 50 µmol/kg as shown in next section. In addition, metabolism of both T-Cho and TG was impaired more extensively in Pparα null than wildtype mice.
Histology
In PFOA wild-type mice, PFOA induced hepatocellular hypertrophy. The liver parenchyma showed dosedependent eosinophilic cytoplasmic changes that were morphologically consistent with peroxisome proliferation (Fig. 1A-D) . However, no fat droplets or focal necrosis were observed in control or treated mice at any doses. Bile duct epithelium showed a slight increase in thickness, which suggested that slight cholangiopathy occurred at 25 and 50 µmol/kg (Fig. 1C, D) .
The histological appearance in control Pparα-null mice showed greater occurrence of microvesicular steatosis than in wild control mice (Fig. 1E) . In PFOA-treated Pparα-null mice, the hepatocytes showed not only hepatocellular hypertrophy, but also cytoplasmic vacuolation and an increase in microvesicular steatosis (Fig. 1F-H) . Focal necrosis was detectable at 50 µmol/kg (Fig. 1I) . The most characteristic change was cholangiopathy. Although it was found in both wild and Pparα-null mice treated with PFOA at 25 ( Fig. 1C and G) and 50 µmol/kg ( Fig. 1D and H) , it was more intensive in the latter than in the former (Fig. 1C, D, G, H) . In particular, it was shown in Pparα-null mice that bile ducts were surrounded by a few inflammatory cells and areas of fibrosis and bile plaque (Fig. 1H) . TUNEL staining demonstrated increased apoptosis in hepatic cells, hepatic arterial walls and bile-duct epithelium in wild-type mice treated with PFOA at 25 and 50 µmol/kg ( Fig. 2A, B, E, F) . On the other hand, in Pparα-null mice, positive staining was observed mainly in bile duct epithelium at 25 and 50 µmol/kg (Fig. 2C, D,  G, H) .
The ultrastructure of livers from control wild-type mice (Fig. 3A) exhibited numerous glycogen granules, normal lamellar arrangement of the rough endoplasmic reticulum (RER), a few normal dense peroxisomes and mitochondria. In contrast to control livers, treated wild-type mice (Fig. 3B-D) displayed dose-dependent, hepatocyte hypertrophy, reduction or disappearance of glycogen granules, degranulation and disruption of the RER, nuclear vacuoles, extensive peroxisome proliferation, and slight proliferation of mitochondria. There were larger numbers and sizes of dark-staining peroxisomes and increased small, round-shaped mitochondria (Fig. 3B-D, I ).
In control Pparα-null mice (Fig. 3E) there were discernible amounts of small fat deposits in the cytoplasm. In treated Pparα-null mice (Fig. 3F-H) there were dosedependent hepatocyte hypertrophy, decreased amounts of glycogen granules, degranulation and disruption of the RER, and increased numbers of mitochondria. There is increased cytoplasmic lipid accumulation to varying extents, extensive mitochondrial changes that consisted of slight swelling, decreased matrix density and inconspicuous criste, but no peroxisome proliferation (Fig. 3F-H, J) . In addition, bile duct epithelium showed degradation of cytoplasmic structure, vacuolization, and disintegration of nuclei and organelles. Severe bile duct epithelium injury was observed, with periductal infiltration of fibroblasts and macrophages, and fibrosis (Fig. 3K) .
Pharmacokinetics of PFOA in whole blood, bile and liver (Table 3)
In order to investigate whether the absence of PPARα changed the pharmacokinetics of PFOA, the concentration of PFOA was determined in whole blood, bile and liver after dosing for 4 wk. The concentrations of PFOA in whole blood increased in proportion to dose, in both wild-type and Pparα-null mice (Table 3) . On the other hand, the concentrations in liver reached similar saturation levels at 12.5 µmol/kg in wild-type and Pparα-null mice.
The concentrations of PFOA in bile increased with dose; it increased by 13.8 times from 56.8 µg/ml at 12.5 µmol/kg to 784 µg/ml at 25 µmol/kg, and 38 times to 2,174 µg/ml at 50 µmol/kg in wild-type mice. Enhanced PFOA excretion indicates that the liver has a PFOA transport capacity from hepatocytes to bile duct that can be mediated at least partly by PPARα. In contrast, much lower increases were observed in Pparα-null mice. PFOA concentrations increased by 3.2 times from 19.6 µg/ml at 12.5 µmol/kg to 62.9 µg/ml at 25 µmol/kg, and by 19.5 times to 383.0 µg/ml at 50 µmol/kg, demonstrating existence of capacity-limited and PPARα-independent PFOA transport.
8-OHdG levels in liver and quantitative RT-PCR of TNF-α mRNA
In wild-type mice, PFOA did not elevate the levels of 8-OHdG in liver significantly at any dose (Fig. 4A) . In contrast, in Pparα-null mice, the levels of 8-OHdG tended to increase dose-dependently (p<0.05), which was significantly increased at 50 µmol/kg (p<0.05) (Fig. 4A) . PFOA did not alter the levels of TNF-α mRNA in wildtype mice (Fig. 4B) . However, PFOA upregulated TNF-α mRNA significantly at doses of 25 and 50 µmol/kg in Pparα-null mice (p<0.01 and p<0.05, respectively) (Fig. 4B) .
These data demonstrated that ablation of PPARα exacerbated oxidative damage and enhanced production of inflammatory cytokines after PFOA administration.
Quantitative RT-PCR for Mdr2, bile acids/phospholipids ratio in bile
We investigated three prototypical hepatobiliary transporters. MDR2 transports biliary phospholipids from hepatocytes to bile via the canalicular phospholipid flippase, which alleviates bile acid toxicity in cholangiocytes 20) . BSEP transports bile acid from hepatocytes to bile via the canaliculi to keep bile acid concentrations constant in bile 21, 22) , and confers resistance to canalicular damages in humans 23) . MRP2 is a transporter of bile acid and is a sensitive indicator of canalicular damages 24) . Recently, PFOA has been reported to regulate liver transporters, organic anion transporting polypeptides (OATPs) and multidrug resistance-associated proteins responsible for uptake of bile acids (BAs) and other organic compounds into liver, primarily via activation of PPARα 25, 26) . For investigating expression of MDR2, we performed quantitative RT-PCR instead of Western blotting because the MDR2 antibody was not specific for mouse MDR2 (data not shown). In wild-type mice, the expression of Mdr2 mRNA was significantly upregulated by PFOA at 12.5, 25 and 50 µmol/kg (p<0.05, p<0.01 and p<0.01, respectively) (Fig. 4C) . In Pparα-null mice, Mdr2 mRNA was not induced by PFOA at 12.5 µmol/kg, however, it was induced significantly at 25 and 50 µmol/kg (p<0.05 and p<0.01, respectively) (Fig. 4C) . This non-PPARα-mediated increase in Mdr2 mRNA may likely be attributable to the increase in bile acid at high doses 27) or other nuclear receptors 28) . To confirm adaptive phospholipid transport, we examined the biliary bile acid to phospholipid (BA/PL) ratio (Fig. 4D) . As expected, BA/PL ratio decreased significantly in a dose-dependent manner in PFOA-treated wild-type mice (p<0.01). However, no such significant adaptation was observed in PFOA-treated Pparα-null mice, suggesting that bile duct protective mechanism characterized by increasing phospholipid transport into bile did not work in the null mice.
Western blotting for BSEP and MRP2
Protein levels of BSEP were downregulated in treated wild-type mice significantly at 50 µmol/kg (p<0.01). In contrast, in Pparα-null mice, protein level of BSEP was increased significantly at 12.5 µmol/kg (p<0.01), however decreased significantly at 50 µmol/kg (p<0.05) (Fig. 5) . The decreased levels of BSEP in Pparα-null mice were very likely induced by severe injury of the hepatobiliary system and inflammation 29, 30) . Protein levels of MRP2 decreased in both wild-type mice and Pparα-null mice at 50 µmol/kg (p<0.05 for both types) (Fig. 5) .
Bile duct transporters demonstrated that there were several PPARα-mediated adaptive responses in wild-type mice to alleviate toxicity of PFOA, such as up-regulation of Mdr2 mRNA and down-regulation of BSEP. In contrast, these responses were not mobilized in concert in PFOA-treated Pparα-null mice. Ablation of PPARα made mice highly susceptible to bile duct injury. MRP2 protein levels decreased in both wild-type and Pparα-null mice, which might be independent to PPARα.
To embark this study, we have hypothesized that PFOA has a potential toxicity for bile duct as Bezafibrate does 9) . As expected, PFOA was shown to induce cholestatic lesions more intensively in Pparα null mice than in wild mice as demonstrated by clinical and pathological inves- Biliary BA/PL ratios show significant decrease in wild-type mice treated with PFOA dose-dependently (p<0.05). However, no such significant adaptation is observed in Pparα-null mice treated with PFOA. Data are presented as mean ± SD. Trend test is Jonckheere's test. *p<0.05, **p<0.01 versus control controls in each group. Log-transformation was performed for expressions of Mdr2 mRNA levels due to heteroscedusticity.
tigations. Simultaneously, we could demonstrate clear differences in dose dependent mobilization of transporters, Mdr2 mRNA and BSEP, between wild and null mice. Furthermore, there were differences in inducing 8-OHdG, TNF-α induction and BA/PL ratios in bile between wild and null mice. This is the first study to demonstrate a potential toxicity of PFOA associated with cholestatic disease and PPARα dependent and independent responses.
Although hepatomegaly and increases in AST and ALT were observed in both wild-type and Pparα null mice, microscopic appearance and ultrastructure of liver indicated different modes of toxicity as evidenced by biomarkers investigated in this study.
In terms of the mechanism of bile duct injury, we focused on the changes in bile compositions and expression levels of hepatobilliary transporters. BA/PL ratio was decreased immediately in PFOA-treated wild-type mice. On the contrary it was increased at 12.5 µmol/kg and decreased gradually at higher PFOA dose in Pparα-null mice. In wild-type mice, the decreased BA/PL ratio may protect against bile duct-injury. Expression of Mdr2 mRNA was clearly upregulated in all treated wild-type mice, whereas it was less upregulated in Pparα-null mice, which was consistent with BA/PL ratio in both groups of mice. The bile acid transporter, BSEP, also showed different responses between wild and null mice. Decreased BSEP levels were observed in both genetic background mice at higher doses, while Pparα-null mice showed a transient increase in BSEP protein levels at lowest dose, 12.5 µmol/kg. Although the entire signal transduction for eliciting responses remains unknown, several other factors such as farnesoid X receptor-α (FXRα), which is known to downregulate BSEP [31] [32] [33] and CAR 28) may also be involved. There is a significant decrease in BSEP protein level in wild-type mice treated with PFOA at 50 µmol/kg (p<0.01). In Pparα-null mice treated with PFOA, the levels are increased significantly at 12.5 µmol/kg (p<0.01), however decreased significantly at 50 µmol/kg (p<0.05). There is a significant decrease in MRP2 protein levels in both wild-type and Pparα-null mice treated with PFOA at 50 µmol/kg (p<0.05). Control wild-type mice, w0; wild-type mice PFOA treated with 12.5 µmol/kg, w12.5; 25 µmol/kg, w25, 50 µmol/kg, w50; control Pparα-null mice, n0; Pparα-null mice treated with PFOA at 12.5 µmol/kg, n12.5; 25 µmol/kg, n25, 50 µmol/kg, n50. Black bars, wild-type mice; white bars, Pparα-null mice. Densitometric values are presented as mean ± SD of 3 animals in each group. *p<0.05, **p<0.01 versus control in each group. Trend test is Jonckheere's test.
In conclusion, this study revealed the new insights that PPARα is protective against cholestastis induced by the weak PPARα ligand PFOA in using mouse model. PFOA mobilized adaptive processes regulated by PPARα-fat metabolism by mitochondria and peroxisomes, oxidative stress, elevation of TNF-α and hepatobiliary transport systems. So we propose that PPARα activators may induce either hepatocellular or bile duct injury, depending on their affinity to PPARα and dose level. If so, cholestasis and its associated morbidities may also be taken into account for risk assessment of PFOA in humans since species differences is well characterized in PPARα-associated signal transduction 34) . Further studies are needed to clarify this hypothesis.
